Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue

Primary outcome measure: Evaluation of viability, security and tolerance of the adipose-derived mesenchymal stem cells implant (ASCs) in fistulizing Crohn's disease patients, collecting the reactions and adverse events occurred during the study. Secondary outcome measures: 1. Evaluating the Adipose-derived mesenchymal stem cells therapeutic effect, in particular: * Fistulas healing efficiency * Changes in quality of life in patients treated * Changes of systemic Crohn's disease after implant * Relapse rate monitored among patients who achieved Adipose-derived mesenchymal Stem Cells treatment success. 2. Achieving the biological characterization of the cell product used and its correlation with the therapeutic effect measured with: * Phenotype study * Suppressor capacity study. * Citoquines production analysis